SCHEMBL6476163

SCHEMBL6476163

CN(C)c1ccc(Nc2ccc(CCc3ccc(Cl)c(Cl)c3)cc2)c(C(=O)O)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
RECQL P46063 1/20 0.67
BLM P54132 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
AKR1C3 P42330 9/20 0.44
AKR1C2 P52895 9/20 0.44
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
FFAR1 O14842 1/20 0.42
SIRT2 Q8IXJ6 1/20 0.41
CNR1 P21554 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
GRIN1 Q05586 2/20 0.38
GRIN2B Q13224 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6484983 0.89 MEN1 (0.65) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6481999 0.87 MEN1 (0.62) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6475081 0.86 MEN1 (0.49) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6483026 0.85 MEN1 (0.60) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6475983 0.85 MEN1 (0.72) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6475930 0.83 MEN1 (0.73) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6475798 0.82 MEN1 (0.72) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6475183 0.82 TDP1 (0.72) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6474530 0.82 MEN1 (0.68) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6482206 0.81 MEN1 (0.66) MEN1KMT2ARECQLBLMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US claimed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP claimed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO claimed
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MEN1 474/4885KMT2A 4729/4885RECQL 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.